research Therapeutic Response of Alopecia Areata‐Associated Nail Changes to Baricitinib
Baricitinib may effectively treat nail changes in alopecia areata.
Search
for
Sort by
Research
720-750 / 1000+ results 
research Efficacy of Oral Apremilast in The Treatment of Alopecia Areata, at The Tertiary Care Hospital, Karachi
Oral Apremilast effectively treats alopecia areata in most patients.
research Responses to Tetanus and Meningococcal Vaccines in Patients with Alopecia Areata Treated with Ritlecitinib
research 081 Simvastatin reduces autoimmune alopecia through direct action on T lymphocytes
Simvastatin helps hair regrowth in autoimmune alopecia by directly affecting T cells.
research 4 Anti-androgens in gynaecological practice
Cyproterone acetate is effective for treating hirsutism and acne in women by blocking androgens in the skin and also works as a contraceptive.
research Systemic tofacitinib in paediatric alopecia areata
research Supplementary Material for: Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.
research Therapeutic synergy between contact dermatitis from a wig‐fixing device and tofacitinib on alopecia areata
A man's hair regrew from alopecia areata after using tofacitinib and experiencing contact dermatitis from a wig device.
research Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis
Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.
research EFFECT OF "AMINOPTERIN" ON EPITHELIAL TISSUES
Aminopterin strongly suppresses epithelial tissues and can treat certain skin conditions but has significant side effects.
research Consecutive Cyproterone Acetate and Estradiol Treatment in Late-Pubertal Transgender Female Adolescents
Cyproterone acetate treatment is safe and causes mild feminization, which increases with added estrogen.
research The manipulation of the cedrol metabolism pathway by baricitinib and its immune interaction mechanism against chemotherapy-induced alopecia
research Tumor Necrosis Factor-α and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice
Blocking certain proteins can reduce skin inflammation caused by cancer treatment.
research Oral Low-Dose Naltrexone in the Treatment of Frontal Fibrosing Alopecia and Lichen Planopilaris: An Uncontrolled Open-Label Prospective Study
Low-dose naltrexone may help reduce redness in certain scalp conditions.
research Exacerbation of alopecia areata during pegylated interferon alpha-2b and ribavirin therapy, possibly due to the collapse of hair follicle immune privilege
A woman's hair loss worsened after starting hepatitis C treatment due to immune changes in her hair follicles.
research Reduced serum vitamin B12 levels during oral cyproterone-acetate and ethinyl-oestradiol therapy in women with diffuse androgen-dependent alopecia
Taking cyproterone acetate and ethinyl oestradiol for hair loss can lower vitamin B12 levels in women.
research EFFECT OF "AMINOPTERIN" ON EPITHELIAL TISSUES
Aminopterin effectively improves skin conditions but has toxic side effects that need careful monitoring.
research Ichthyosis follicularis, alopecia and photophobia (IFAP) syndrome treated with acitretin
Acitretin moderately improved skin and eye issues but not hair loss or light sensitivity in a 3-year-old with IFAP syndrome.
research Oral tofacitinib monotherapy in Korean patients with refractory moderate-to-severe alopecia areata: A case series
Tofacitinib is effective and safe for treating severe hair loss in Korean patients.
research Excimer Laser: A Module of the Alopecia Areata Common Protocol
The excimer laser may help hair regrow in alopecia areata patients.
research 원저 : Mohs 미세도식 수술을 이용한 안검부 기저세포암의 준임상적 침윤 유형에 관한 연구
Oral minipulse therapy with betamethasone effectively promotes hair regrowth in alopecia areata with fewer side effects.
research Baricitinib Provides Holistic Improvement in Scalp, Eyebrow and Eyelash Regrowth in Adolescents With Severe Alopecia Areata
Baricitinib helps regrow scalp, eyebrow, and eyelash hair in teens with severe alopecia areata.
research Efficacy and safety of tofacitinib in patients with total and universal alopecia- A retrospective evaluation of 69 patients
Tofacitinib is effective for treating alopecia totalis and universalis, with some patients experiencing significant hair regrowth.
research Upadacitinib for the Management of Alopecia Totalis and Subtotalis in Pediatric Patients: A Case Series
Upadacitinib may help regrow hair in children with alopecia areata and is generally safe.
research Androgen metabolism in hirsute patients treated with cyproterone acetate
Cyproterone acetate effectively reduced hair growth in hirsute patients by lowering androgen levels and altering androgen metabolism.
research Alopecia universalis with IL-12-RB1 and STAT4 mutations effectively treated with upadacitinib
Upadacitinib successfully regrew hair in a child with alopecia universalis and specific genetic mutations.
research Image 3_Associations between ionomic profile and metabolic abnormalities in a murine model of sodium sulfide induced alopecia areata.tif
Linoleic acid and magnesium are key in alopecia areata progression, and tofacitinib can help by affecting their pathway.
research Sublingual tofacitinib for alopecia areata: a roll‐over pilot clinical trial and analysis of pharmacokinetics
The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.
research Selective delivery of adapalene to the human hair follicle under finite dose conditions using polymeric micelle nanocarriers
Polymeric micelle nanocarriers deliver adapalene more effectively to hair follicles than commercial products.
research 43046 Outcomes of Down-Titration in Patients with Severe Scalp Alopecia Areata Treated with Baricitinib 4 Mg: Week 104 Data from BRAVE-AA2
Reducing the dose of Baricitinib to 2mg led to a loss of hair regrowth benefits in nearly half of the patients by Week-104.